NO320128B1 - Fremgangsmate for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-losningsmiddel - Google Patents
Fremgangsmate for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-losningsmiddel Download PDFInfo
- Publication number
- NO320128B1 NO320128B1 NO19993779A NO993779A NO320128B1 NO 320128 B1 NO320128 B1 NO 320128B1 NO 19993779 A NO19993779 A NO 19993779A NO 993779 A NO993779 A NO 993779A NO 320128 B1 NO320128 B1 NO 320128B1
- Authority
- NO
- Norway
- Prior art keywords
- solvent
- compound
- water
- slurry
- propanol
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 52
- 239000012296 anti-solvent Substances 0.000 title claims abstract description 46
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 title description 3
- 239000002904 solvent Substances 0.000 claims abstract description 86
- 238000002425 crystallisation Methods 0.000 claims abstract description 33
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims abstract description 32
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 78
- 239000002002 slurry Substances 0.000 claims description 73
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- 230000008025 crystallization Effects 0.000 claims description 30
- 239000000463 material Substances 0.000 claims description 27
- 238000001035 drying Methods 0.000 claims description 14
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000227 grinding Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 230000004580 weight loss Effects 0.000 claims description 6
- 238000002411 thermogravimetry Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 3
- 238000003801 milling Methods 0.000 claims description 2
- 239000013618 particulate matter Substances 0.000 claims description 2
- 238000010583 slow cooling Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 239000011877 solvent mixture Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 description 30
- 239000000047 product Substances 0.000 description 15
- 239000012467 final product Substances 0.000 description 5
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 5
- 239000007858 starting material Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 3
- 238000005185 salting out Methods 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical compound C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- PUYCICVJCRLABY-UHFFFAOYSA-N heptane;oxolane Chemical compound C1CCOC1.CCCCCCC PUYCICVJCRLABY-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3738597P | 1997-02-05 | 1997-02-05 | |
GBGB9706046.1A GB9706046D0 (en) | 1997-03-24 | 1997-03-24 | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent |
US4280797P | 1997-04-08 | 1997-04-08 | |
GBGB9709348.8A GB9709348D0 (en) | 1997-05-07 | 1997-05-07 | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent |
PCT/US1998/001999 WO1998033782A1 (en) | 1997-02-05 | 1998-02-02 | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent |
Publications (3)
Publication Number | Publication Date |
---|---|
NO993779D0 NO993779D0 (no) | 1999-08-04 |
NO993779L NO993779L (no) | 1999-10-05 |
NO320128B1 true NO320128B1 (no) | 2005-10-31 |
Family
ID=27451618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19993779A NO320128B1 (no) | 1997-02-05 | 1999-08-04 | Fremgangsmate for krystallisering av en revers transkriptaseinhibitor ved anvendelse av et anti-losningsmiddel |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0975609B1 (ru) |
JP (6) | JP3418626B2 (ru) |
KR (1) | KR100573192B1 (ru) |
CN (2) | CN1191242C (ru) |
AT (1) | ATE486065T1 (ru) |
AU (1) | AU738545C (ru) |
CA (1) | CA2279198C (ru) |
CZ (2) | CZ297535B6 (ru) |
DE (1) | DE69841972D1 (ru) |
EA (1) | EA001805B1 (ru) |
EE (1) | EE03827B1 (ru) |
HU (1) | HU229087B1 (ru) |
IL (1) | IL130715A (ru) |
NO (1) | NO320128B1 (ru) |
NZ (1) | NZ336510A (ru) |
PL (1) | PL197740B1 (ru) |
SK (1) | SK284935B6 (ru) |
WO (1) | WO1998033782A1 (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998033782A1 (en) * | 1997-02-05 | 1998-08-06 | Merck & Co., Inc. | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent |
US6015926A (en) * | 1997-05-16 | 2000-01-18 | Merck & Co., Inc. | Efficient enantioselective addition reaction using an organozinc reagent |
US20010014352A1 (en) | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
HRP990182A2 (en) * | 1998-06-11 | 2000-02-29 | Du Pont Pharm Co | Crystalline efavirenz |
GB9828721D0 (en) * | 1998-12-24 | 1999-02-17 | Glaxo Group Ltd | Novel apparatus and process |
WO2006018853A2 (en) | 2004-08-19 | 2006-02-23 | Hetero Drugs Limited | Novel polymorphs of efavirenz |
WO2008108630A1 (en) * | 2007-03-02 | 2008-09-12 | Ultimorphix Technologies B.V. | Polymorphic forms of efavirenz |
WO2009087679A2 (en) * | 2007-12-24 | 2009-07-16 | Matrix Laboratories Limited | Process for preparing polymorphic forms of (s)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one |
ES2445090T3 (es) | 2008-12-22 | 2014-02-28 | Hetero Research Foundation | Procedimiento para preparar un polimorfo de efavirenz |
DE102009041443A1 (de) | 2009-09-16 | 2011-03-31 | Archimica Gmbh | Salze des 6-Chlor-4-(cyclopropylethinyl)-1,4-dihydro-4-(trifluormethyl)-2H-3,1-benzoxazin-2-ons und deren Synthese, Aufreinigung und Anwendung als Vorstufen für Efavirenz |
EP2471783A1 (en) | 2010-12-23 | 2012-07-04 | Esteve Química, S.A. | Novel polymorphic form of efavirenz |
CN103508973B (zh) * | 2012-06-25 | 2016-04-27 | 上海迪赛诺药业有限公司 | 制备依非韦伦i型结晶的方法 |
CN105037175B (zh) * | 2014-07-18 | 2017-02-22 | 盐城迪赛诺制药有限公司 | 一种用于提高依非韦伦中间体光学纯度的方法 |
US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
SG11201802990RA (en) | 2015-10-16 | 2018-05-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
CN114195761B (zh) * | 2021-12-23 | 2023-04-14 | 浙江普洛家园药业有限公司 | 一种高纯度西他沙星3/2水合物的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1282405C (en) * | 1984-05-21 | 1991-04-02 | Michael R. Violante | Method for making uniformly sized particles from water-insoluble organic compounds |
US5519021A (en) * | 1992-08-07 | 1996-05-21 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
IL106507A (en) * | 1992-08-07 | 1997-11-20 | Merck & Co Inc | Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type |
AU1694295A (en) * | 1994-01-28 | 1995-08-15 | Merck & Co., Inc. | Benzoxazinones as inhibitors of hiv reverse transcriptase |
US5663467A (en) * | 1995-01-23 | 1997-09-02 | Merck & Co., Inc. | Synthesis of cyclopropylacetylene |
US5633405A (en) * | 1995-05-25 | 1997-05-27 | Merck & Co., Inc. | Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one |
WO1998033782A1 (en) * | 1997-02-05 | 1998-08-06 | Merck & Co., Inc. | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent |
IL132185A0 (en) * | 1997-04-07 | 2001-03-19 | Pont Pharmaceuticals Company M | Asymmetric synthesis of benzoxazinones via new intermediates |
-
1998
- 1998-02-02 WO PCT/US1998/001999 patent/WO1998033782A1/en active IP Right Grant
- 1998-02-02 CN CNB011227095A patent/CN1191242C/zh not_active Expired - Lifetime
- 1998-02-02 AU AU62632/98A patent/AU738545C/en not_active Expired
- 1998-02-02 DE DE69841972T patent/DE69841972D1/de not_active Expired - Lifetime
- 1998-02-02 EP EP98904853A patent/EP0975609B1/en not_active Expired - Lifetime
- 1998-02-02 CZ CZ0276599A patent/CZ297535B6/cs not_active IP Right Cessation
- 1998-02-02 AT AT98904853T patent/ATE486065T1/de active
- 1998-02-02 CZ CZ20040883A patent/CZ304186B6/cs not_active IP Right Cessation
- 1998-02-02 KR KR1019997006985A patent/KR100573192B1/ko not_active IP Right Cessation
- 1998-02-02 SK SK1055-99A patent/SK284935B6/sk not_active IP Right Cessation
- 1998-02-02 CA CA002279198A patent/CA2279198C/en not_active Expired - Lifetime
- 1998-02-02 HU HU0001313A patent/HU229087B1/hu unknown
- 1998-02-02 NZ NZ336510A patent/NZ336510A/en not_active IP Right Cessation
- 1998-02-02 IL IL13071598A patent/IL130715A/xx not_active IP Right Cessation
- 1998-02-02 EE EEP199900341A patent/EE03827B1/xx unknown
- 1998-02-02 PL PL334478A patent/PL197740B1/pl unknown
- 1998-02-02 JP JP53319098A patent/JP3418626B2/ja not_active Expired - Lifetime
- 1998-02-02 EA EA199900720A patent/EA001805B1/ru not_active IP Right Cessation
- 1998-02-02 CN CN98802171A patent/CN1073991C/zh not_active Expired - Lifetime
-
1999
- 1999-08-04 NO NO19993779A patent/NO320128B1/no not_active IP Right Cessation
-
2002
- 2002-06-04 JP JP2002163198A patent/JP2003040874A/ja not_active Withdrawn
-
2010
- 2010-09-10 JP JP2010202879A patent/JP5295190B2/ja not_active Expired - Lifetime
-
2013
- 2013-04-22 JP JP2013089216A patent/JP2013139484A/ja active Pending
-
2015
- 2015-07-24 JP JP2015146631A patent/JP6126172B2/ja not_active Expired - Lifetime
-
2017
- 2017-01-11 JP JP2017002745A patent/JP2017061575A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6126172B2 (ja) | 逆溶媒を使用する逆転写酵素阻害剤の結晶化方法 | |
US20060009641A1 (en) | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one | |
RU2275354C2 (ru) | Способы получения кристаллов в-типа натеглинида | |
AU739211B2 (en) | Crystalline macrolides and process for their preparation | |
JP2024038090A (ja) | 2,2,2-トリフルオロ酢酸1-(2,4-ジメチルフェニル)-2-[(3-メトキシフェニル)メチレン] ヒドラジド多形体およびその製造方法 | |
KR20140108222A (ko) | 결정질 형태의 신속한 식별 및 제조를 위한 방법 | |
JPH08333364A (ja) | d4 T多形フォームI方法 | |
AU760075B2 (en) | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent | |
ES2353458T3 (es) | Procedimiento para la cristalización de un inhibidor de transcriptasa inversa usando un anti-solvente. | |
CN113683607B (zh) | 一种特力利汀中间体晶型ii及其制备方法 | |
MXPA99007215A (en) | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent | |
HUE025398T2 (en) | New crystalline modification of CDB-4124 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |